Jeffrey Humphrey
Directeur Technique/Scientifique/R&D chez LANTHEUS HOLDINGS, INC.
Fortune : 742 689 $ au 31/03/2024
Profil
Jeffrey S.
Humphrey is currently the Chief Medical Officer at Lantheus Holdings, Inc. Prior to his current position, he served as the Chief Medical Officer at Constellation Pharmaceuticals, Inc. and Magenta Therapeutics, Inc. He also held the role of Independent Director at Cyteir Therapeutics, Inc. and served as the Chief Development Officer at Kyowa Kirin Co., Ltd.
Jeffrey's former positions include Senior Vice President-Drug Development at Kyowa Hakko Kirin Pharma, Inc. and President & Chief Medical Officer at Kyowa Kirin Pharmaceutical Development Ltd.
He obtained his undergraduate degree from Harvard College and his doctorate from Case Western Reserve University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
LANTHEUS HOLDINGS INC
0,01% | 17/06/2024 | 9 076 ( 0,01% ) | 742 689 $ | 31/05/2024 |
| 05/10/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Jeffrey Humphrey
| Sociétés | Poste | Début |
|---|---|---|
| LANTHEUS HOLDINGS, INC. | Directeur Technique/Scientifique/R&D | 28/05/2024 |
Anciens postes connus de Jeffrey Humphrey
| Sociétés | Poste | Fin |
|---|---|---|
| CYTEIR THERAPEUTICS, INC. | Directeur/Membre du Conseil | 29/11/2023 |
| MAGENTA THERAPEUTICS | Directeur Technique/Scientifique/R&D | 01/08/2022 |
| CONSTELLATION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | 15/07/2021 |
| KYOWA KIRIN CO. LTD. | Corporate Officer/Principal | 01/06/2020 |
Kyowa Kirin Pharmaceutical Development Ltd.
 Kyowa Kirin Pharmaceutical Development Ltd. Miscellaneous Commercial ServicesCommercial Services Kyowa Kirin Pharmaceutical Development Ltd. engages in developing pharmaceutical products. The company was founded on December 31, 1996 and is headquartered in London, the United Kingdom. | President | 01/08/2019 |
Formation de Jeffrey Humphrey
| Harvard College | Undergraduate Degree |
| Case Western Reserve University School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| KYOWA KIRIN CO. LTD. | Health Technology |
| LANTHEUS HOLDINGS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
| Kyowa Hakko Kirin Pharma, Inc. | |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
Cyteir Therapeutics, Inc.
 Cyteir Therapeutics, Inc. BiotechnologyHealth Technology Cyteir Therapeutics, Inc.is a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. The company was founded by Kevin Mills and Timothy Romberger in June 2012 and is headquartered in Lexington, MA. | Health Technology |
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Kyowa Kirin Pharmaceutical Development Ltd.
Kyowa Kirin Pharmaceutical Development Ltd. Miscellaneous Commercial ServicesCommercial Services Kyowa Kirin Pharmaceutical Development Ltd. engages in developing pharmaceutical products. The company was founded on December 31, 1996 and is headquartered in London, the United Kingdom. | Commercial Services |
